Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA Animal Free,Azide Free,Carrier Free,ExactAb™,Low Endotoxin,Recombinant,Validated for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C,Avoid repeated freezing and thawing Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 2 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Emibetuzumab (anti-MET) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab (anti-MET) shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab (anti-MET) can be used in study of cancer.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg
Emibetuzumab (anti-MET) (Ab170880) - Flow Cytometry
Flow Cytometry analysis of HepG2 cells labelling MET (red) with Emibetuzumab (anti-MET) (Ab170880). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Emibetuzumab (anti-MET) (Ab170880) - SEC
The purity of Emibetuzumab (anti-MET) (Ab170880) is more than 95% verified by HPLC.
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F1001469 | Certificate of Analysis | Nov 01, 2023 | Ab170880 |
| ZJ23F1001470 | Certificate of Analysis | Nov 01, 2023 | Ab170880 |
| 1. Lianbao Ye, Yuanxin Tian, Zhonghuang Li, Hong Jin, Zhengguang Zhu, Shanhe Wan, Junyan Zhang, Pengjiu Yu, Jiajie Zhang, Shuguang Wu. (2012) Design, synthesis and molecular docking studies of some novel spiro[indoline-3, 4′-piperidine]-2-ones as potential c-Met inhibitors. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, [PMID:22381355] [10.1016/j.ejmech.2012.02.016] |
| 2. Lianbao Ye, Xiaomin Ou, Yuanxin Tian, Bangwei Yu, Yan Luo, Binghong Feng, Hansen Lin, Jiajie Zhang, Shuguang Wu. (2013) Indazoles as potential c-met inhibitors: Design, synthesis and molecular docking studies. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, [PMID:23702473] [10.1016/j.ejmech.2013.04.004] |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Animal Free grade guide → View Carrier Free grade guide → View Recombinant grade guide → View Validated grade guide → View ExactAb™ grade guide → View Low Endotoxin grade guide → View Azide Free grade guide →
